Palos Verdes Medical Group — Rolling Hills Estates, California

Palos Verdes Medical Group is a clinical research site located in Rolling Hills Estates, California, United States 90274.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Palos Verdes Medical Group has participated in 1 clinical trials.

Therapeutic areas: Peanut Allergy.

Sponsors: DBV Technologies.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Rolling Hills Estates

Browse all research sites in California · View every site in Rolling Hills Estates

• Peninsula Research Associates
• GSK Investigational Site
• Research Site
• Regeneron Investigational Site
• Investigational Site Number 840014
• Novartis Investigative Site
• Regeneron Study Site
• Lawrence Sher, M.D.
• Penninsula Research Associates
• Pfizer Investigational Site
• Pearl Investigative Site
• Peninsula Research Associates Pra

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Palos Verdes Medical Group?

Palos Verdes Medical Group has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Palos Verdes Medical Group conducted?

Palos Verdes Medical Group has 1 clinical trials on record. Their work covers Peanut Allergy.

Is Palos Verdes Medical Group accredited by Crixeo Clinical Trials?

Palos Verdes Medical Group has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Palos Verdes Medical Group?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.